Motexafin lutetium

From Wikipedia, the free encyclopedia
  (Redirected from Antrin)
Jump to navigation Jump to search
Motexafin lutetium
Motexafin lutetium.png
Other names
Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
3D model (JSmol)
Molar mass 1,166.14 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☑Y verify (what is ☑Y‹See TfM›☒N ?)
Infobox references

Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.

It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.

It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).[1]

It is photoactivated by 732 nm light which allows greater depth of penetration.[2]

Clinical trials[edit]

Phase II clinical trials were in progress in 1999.[3]

A phase I trial for prostate cancer reported in 2009.[4]


  1. ^ Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease Archived 2011-07-16 at the Wayback Machine., 2002
  2. ^ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
  3. ^ Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT Archived 2012-07-13 at, 1999
  4. ^ Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM; Busch, TM (2008). "Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA". Clinical Cancer Research. 14 (15): 4869–76. doi:10.1158/1078-0432.CCR-08-0317. PMC 2680073. PMID 18676760.